Gul Ozen Oz, Cander Soner, Gul Bulent, Açıkgoz Ebru, Sarandol Emre, Ersoy Canan
Uludag University Medical School, Department of Endocrinology and Metabolism, Bursa, Turkey.
Sevket Yilmaz Education and Reserach Hospital, Department of Endocrinology and Metabolism, Bursa, Turkey.
Eur Cytokine Netw. 2015 Oct-Dec;26(4):73-8. doi: 10.1684/ecn.2015.0370.
This study was designed to evaluate insulin resistance and plasma levels of visfatin and resistin in obese and non-obese patients with polycystic ovary syndrome (PCOS). A total of 37 premenopausal PCOS patients with (n = 18, mean (SD) age: 27.5 (5.7 years) or without obesity (n = 19, mean (SD) age: 23.7 (3.1) years) and healthy volunteers (n = 18, mean (SD) age:29.8 (4.1) years) were included in this study. Data on clinical characteristics, glycemic parameters and lipid parameters were recorded for each subject as were plasma visfatin and resistin levels. Mean (SD) HOMA-IR values were significantly higher in obese PCOS patients (3.4 (1.7)) compared with non-obese PCOS patients (2.0 (1.2), p<0.01) and controls (1.6 (0.8), p<0.01). No significant difference was noted between study groups in terms of plasma resistin (ng/mL) or visfatin (ng/mL) levels. There was no correlation between serum plasma visfatin (r = 0.127, p = 0.407) and resistin (r = -0.096, p = 0.544) levels and HOMA-IR. In conclusion, our findings revealed increased likelihood of metabolic and dyslipidemic manifestations in obese compared to non-obese PCOS patients, while no significant difference was noted in visfatin and resistin levels among PCOS patients in terms of co-morbid obesity and in comparison to controls.
本研究旨在评估肥胖和非肥胖多囊卵巢综合征（PCOS）患者的胰岛素抵抗以及内脂素和抵抗素的血浆水平。本研究共纳入37例绝经前PCOS患者，其中肥胖患者18例（平均（标准差）年龄：27.5（5.7）岁），非肥胖患者19例（平均（标准差）年龄：23.7（3.1）岁），以及健康志愿者18例（平均（标准差）年龄：29.8（4.1）岁）。记录了每位受试者的临床特征、血糖参数、血脂参数以及血浆内脂素和抵抗素水平。肥胖PCOS患者的平均（标准差）HOMA-IR值（3.4（1.7））显著高于非肥胖PCOS患者（2.0（1.2），p<0.01）和对照组（1.6（0.8），p<0.01）。各研究组之间的血浆抵抗素（ng/mL）或内脂素（ng/mL）水平无显著差异。血清血浆内脂素（r = 0.127，p = 0.407）和抵抗素（r = -0.096，p = 0.544）水平与HOMA-IR之间无相关性。总之，我们的研究结果显示，与非肥胖PCOS患者相比，肥胖PCOS患者出现代谢和血脂异常表现的可能性增加，而PCOS患者中，合并肥胖者与对照组相比，内脂素和抵抗素水平无显著差异。
